Influence of preparative regimen and methotrexate for GVHD prophylaxis on engraftment after related cord blood transplant for patients with hemoglobinopathies. An eurocord group analysis

F. Locatelli, V. Rocha, M. Ertem, S. Graphacos, F. Bernaudin, X. Li, B. Brichard, A. Nagler, R. Miniero, I. Roberts, I. Yaniv, P. Lutz, A. Will, T. Raja, F. Garnier, E. Gluckman

Research output: Contribution to journalArticle

Abstract

Autologous reconstitution is a major problem after cord blood transplant (CBT) for patients with hemoglobinopathies (Hbpathies). We analyzed risk factors for neutrophil engraftment in 31 patients with Hbpathies (Sickle cell disease (SCO) n=6, and Thalassemia (Thai) n=25) receiving a related CBT in 15 transplant centers. All CB donors were HLJA matched, except one (1 HLA-A difference). Median recipient age was 5 years (1-19) and median follow-up was 24 months (2-72). At transplant, 19 and 12 patients belonged :o class 1 and class 2 of the Pesaro classification, respectively. One patient with SCO had previously had stroke. As preparative regimen, 17 patients received Cyclophosphamic e (CY) associated to Busulfan (BU) and 14 patients were given CY+BU associated Thiotepa (THIO) (n=9) or Fludarabine (FLU) (n=5). ATG was associated in 12 cases. GVHD prophylaxis consisted of either Cyclosporine A (CsA) alone (n=23) or associated to Methotrexate in 8 cases. Median number of nucleated cells infused was 3.8 x lOVl.g (1.2-10). Prophylactic hematopoietic growth factors (

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART I
Publication statusPublished - 2000

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Locatelli, F., Rocha, V., Ertem, M., Graphacos, S., Bernaudin, F., Li, X., Brichard, B., Nagler, A., Miniero, R., Roberts, I., Yaniv, I., Lutz, P., Will, A., Raja, T., Garnier, F., & Gluckman, E. (2000). Influence of preparative regimen and methotrexate for GVHD prophylaxis on engraftment after related cord blood transplant for patients with hemoglobinopathies. An eurocord group analysis. Blood, 96(11 PART I).